Recent Developments

Clinical Data for X4P-001-IO in Combination with Inlyta® (Axitinib) Demonstrated Encouraging Overall Response Rates (including a Complete Response) and Disease Control Rates in Patients with Clear Cell Renal Cell Carcinoma

X4 Pharmaceuticals, a clinical stage biotechnology company developing a novel CXCR4 inhibitor to improve immune cell trafficking to treat cancer and rare diseases, today announced updated results from the Phase 1 part of an ongoing Phase 1/2 study of X4P-001-IO … Continue reading

Posted in Recent Development News: Q4 - 2017, Recent Developments | Comments Off

First Clinical Data for X4P-001-RD Demonstrating Preliminary Activity in Patients with WHIM Syndrome will be Presented at American Society for Hematology Annual Meeting

X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 inhibitor drugs to improve immune cell trafficking to treat cancer and rare disease, today announced that Dr. David C. Dale, MD will present the first clinical data from an ongoing … Continue reading

Posted in Recent Development News: Q4 - 2017, Recent Developments | Comments Off

X4 Pharmaceuticals Secures $27 Million in Series B Financing

X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 inhibitor drugs to improve immune cell trafficking to treat cancer and rare diseases, today announced the successful completion of a $27 million Series B financing. Proceeds from the financing will … Continue reading

Posted in Recent Development News: Q4 - 2017, Recent Developments | Comments Off

X4 Pharmaceuticals Presents Clinical Data Demonstrating Immune Activation Through CXCR4 Pathway with X4P-001-IO

X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 inhibitor drugs to improve immune cell trafficking to treat cancer and rare diseases, today highlighted data from multiple presentations at the Society for Immunotherapy of Cancer (SITC) Annual Meeting. The … Continue reading

Posted in Recent Development News: Q4 - 2017, Recent Developments | Comments Off

First Clinical Data from Combination of X4P-001- IO and Keytruda® (pembrolizumab) in Patients with Melanoma Will Be Presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 inhibitor drugs to improve immune cell trafficking to treat cancer and rare diseases, today announced that the first data from its ongoing Phase 1b clinical study of X4P-001-IO in patients … Continue reading

Posted in Recent Development News: Q4 - 2017, Recent Developments | Comments Off

Diffusion Pharmaceuticals Appoints Dr. Robert Ruffolo to Board of Directors

Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN), a clinical stage biotechnology company focused on the development of novel small molecule therapeutics for cancer and other hypoxia-related diseases, today announced the appointment of Robert R. Ruffolo, Jr., Ph.D., to its Board of Directors, effective … Continue reading

Posted in Recent Development News: Q3 - 2017, Recent Developments | Comments Off

Edge Therapeutics Announces Commercial Supply Agreement for EG- 1962 with Oakwood Laboratories

Edge Therapeutics, Inc.(Nasdaq:EDGE) today announced that it has entered into a supply agreement and an amended and restated development agreement with Oakwood Laboratories for the commercial manufacturing of EG-1962 for initial product launch and thereafter. EG-1962, an orphan drug and … Continue reading

Posted in Recent Development News: Q3 - 2017, Recent Developments | Comments Off

ROOT9B HOLDINGS ADDED TO RUSSELL MICROCAP® INDEX

- root9B Holdings Inc. (NASDAQ: RTNB), a leading provider of advanced cybersecurity products, services and training, has been added to the Russell Microcap® Index, effective today. Russell Investments reconstituted its family of U.S. indexes after the close of the U.S. … Continue reading

Posted in Recent Development News: Q2 - 2017, Recent Developments | Comments Off

root9B Remains #1 on Cybersecurity 500 For 6th Consecutive Quarter

COLORADO SPRINGS, Colo., June 23, 2017 — In response to remaining #1 on the Cybersecurity 500 for six consecutive quarters, root9B’s Chief Executive Officer Eric Hipkins issued the following statement: “root9B’s continued #1 presence on the Cybersecurity 500 is a … Continue reading

Posted in Recent Development News: Q2 - 2017, Recent Developments | Comments Off

root9B Releases Technical Analysis on Active Malware Campaign After Briefing Law Enforcement

root9B, a root9B Holdings Inc. (NASDAQ: RTNB) company, and leading provider of advanced cybersecurity products, services, and training, has released an in-depth technical analysis report on a newly identified active campaign targeting point-of-sale systems. The report provides technical details of … Continue reading

Posted in Recent Development News: Q2 - 2017, Recent Developments | Comments Off

root9B Releases Technical Analysis on Active Malware Campaign After Briefing Law Enforcement

root9B, a root9B Holdings Inc. (NASDAQ: RTNB) company, and leading provider of advanced cybersecurity products, services, and training, has released an in-depth technical analysis report on a newly identified active campaign targeting point-of-sale systems. The report provides technical details of … Continue reading

Posted in Recent Developments | Comments Off

Edge Therapeutics to Participate in the JMP Securities Life Science Conference

Edge Therapeutics, Inc. (Nasdaq:EDGE), a clinical-stage biotechnology company developing novel hospital-based therapies in the management of acute, life threatening conditions, today announced that President and Chief Executive Officer Brian A. Leuthner will participate in the panel discussion “Hospital Drug Launches … Continue reading

Posted in Recent Development News: Q2 - 2017, Recent Developments | Comments Off